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The mechanisms underlying imatinib resistance in chronic myelogenous leukemia (CML) include BCR-ABL gene rearrangement, overexpression of Bcl-Abl tyrosine kinase fusion protein and activation of Bcr-Abl-independent pathways such as those of Src kinases. 1, 2 Although impressive therapeutic responses have been achieved with imatinib treatment, many patients fail to respond optimally due to innate or acquired resistance. 1, 2 The available treatments for these patients are limited and improved treatment options are urgently needed. In patients with Philadelphia chromosome-positive CML, tyrosyl phosphorylation of the Bcr-Abl oncoprotein enables binding to the Src homology-2 (SH2) domain of the adapter protein growth factor receptor-bound 2 (Grb2), thereby activating downstream signaling pathways, including the Ras/MAPK pathway, controlling cell proliferation. 3 Grb2 mutants missing one of its two SH3 domains impair cell transformation by Bcr-Abl, highlighting the importance of Grb2 interactors, such as SOS1, in oncogenic signaling. 4 These findings also suggest that Grb2 binding antagonists may provide an effective alternative or adjunct therapeutic strategy for CML patients resistant to imatinib.
Small molecule Grb2 SH2 domain binding antagonists have been developed that are selective, potent and phosphatase resistant. 5 These have been shown to block the growth of tumorderived cells in culture as well as tumor angiogenesis and metastasis in mice. 3, 5, 6 We report here that TB03 ( Supplementary  Figure 1 ), a member of this compound class, synergistically enhanced inhibition of K562 leukemia cell proliferation by imatinib ( Figure 1 ). Treatment with TB03 or imatinib alone resulted in dose-dependent growth inhibition (Figures 1a and b); when combined with TB03, imatinib activity was significantly enhanced (Figure 1b ). Combining imatinib with TB03 at a ratio of 1:100 was synergistic and achieved an ED 90 with a combination index (CI) of 0.774. At ratios of 1:50, 1:25, 1:12.5 and 1:6.25, all combinations were synergistic as indicated by CIs at ED 50 , ED 75 or ED 90 values ( Supplementary Table 1 and Figure 1c ).
Flow cytometry experiments were performed to further characterize synergistic inhibition of K562 cell proliferation by the combination of imatinib and TB03. Analysis using annexin V-fluorescein isothiocyanate/propidium iodide double staining showed that treatment with either imatinib or TB03 alone did not affect apoptosis relative to the vehicle control group, but the combination of these two agents increased apoptosis by 450% (20% vs 36%; Figure 1d ), indicating functional complementation of distinct pro-apoptotic effects. Flow cytometry analysis using CellTrace Violet indicated that vehicle-treated K562 cells divided eight times in 72 h. Treatment with 0.25 or 2.5 mM imatinib alone resulted in 0.04% and 0.03% of cells reaching the eighth cell division, respectively, and treatment with 2 mM TB03 alone resulted in 0.08% of cells reaching the eighth cell division ( Figure 1e ). Combined imatinib/TB03 treatments further reduced the number of cells reaching eight divisions: 0.02% for 2 mM TB03 plus 0.25 mM imatinib and 0.01% for 2 mM TB03 plus 2.5 mM imatinib; the latter combination represents an eightfold reduction in cell survival ( Figure 1e ). Short-term analysis of cell cycle progression using Vybrant DyeCycle Green showed that imatinib treatment increased the G0/G1 population while decreasing the S and G2/M phase populations, consistent with cell cycle suppression ( Figure 1f ). Treatment with TB03 alone had little effect, but combined TB03/imatinib treatment increased the number of cells in G0/G1 in a dose-dependent manner, with proportionately fewer cells reaching S and G2/M. The increased number of cells in sub-G1 phase with imatinib treatment relative to control (1.5% vs 4.7%) may reflect pro-apoptotic effects. Consistent with the complementation of apoptosis observed by annexin staining, TB03 plus imatinib further increased the number of cells in this phase in a dose-dependent manner, from 4.7 to 7% for imatinib:TB03 at a ratio 0.5:6.25 mM and from 4.7 to 11% for imatinib:TB03 at 0.5:12.5 mM ( Figure 1f ). These results reinforce the hypothesis that TB03 alone inhibits only cell cycle progression, but enhances imatinib-induced apoptosis and cell cycle suppression, resulting in synergistic inhibition of K562 proliferation.
Cancer stem cells (CSCs) have become prime suspects for mediating resistance to therapy, disease relapse and progression. 7 High levels of aldehyde dehydrogenase (ALDH) activity have been recognized as a CSC marker in many cancers, including leukemia. 8 The effects of imatinib, TB03 and combined imatinib/TB03 treatment on a putative leukemia stem cell subpopulation of K562 was investigated by flow cytometry using ALDEFLUOR, which provides a fluorescent ALDH reaction product to identify stem and progenitor cells by ALDH activity. Among vehicletreated K562 cells 11.4% were ALDH þ , this was unaltered by TB03 treatment but decreased to 8.9% and 2.7% with imatinib treatment at 0.25 and 25 mM, respectively (Supplementary Figure 2 ). When combined with TB03 (20 mM), imatinib at 0.25 and 25 mM concentrations further reduced the ALDH þ K562 population to 5.0% and 1.8%, respectively (Supplementary Figure 2 ). To our knowledge, this is the first evidence of leukemia Accepted article preview online 31 October 2013; advance online publication, 22 November 2013 stem cell suppression by imatinib or by imatinib combined with a Grb2 SH2 domain binding antagonist.
Imatinib competitively inhibits Abl kinase activation, a critical transforming event in CML cases displaying the BCR-ABL gene rearrangement, but the activation of other tyrosine kinasemediated signaling pathways can sustain important SH2 domain-mediated signaling events, including those of Grb2. We therefore investigated imatinib/TB03 synergy at the level of protein tyrosyl phosphorylation and Grb2 recruitment. Immunoblot analysis of K562 cell lysates after 1 h treatment with imatinib alone showed dose-dependent inhibition of multiple protein tyrosyl phosphorylation events relative to vehicle control, including phospho-Bcr-Abl (Figure 2a , arrows). TB03 alone had a modest effect, but the effects of imatinib were clearly enhanced when the two agents were combined (Figure 2a ). Small molecule Grb2 SH2 domain binding antagonists block the binding of Grb2 to the activated growth factor receptor tyrosine kinases and effectors containing the Grb2 SH2 domain recognition motif. 3, 6 As anticipated, immunoprecipitation of Grb2 from intact K562 cells treated with imatinib or TB03 alone, followed by immunoblotting with anti-phosphotyrosine antibody, showed reduced capture of multiple phosphoproteins ranging from 150 to 250 kDa (Figure 2b , left). The combination of TB03 and imatinib further reduced the association of tyrosyl phosphoproteins with Grb2 to the point where almost all bands were undetectable by immunoblotting (Figure 2b, right) . These biochemical effects appear to be the most immediate and direct manifestations of synergy between TB03 and imatinib.
The suppression of Bcr-Abl-driven intracellular protein tyrosyl phosphorylation and adapter protein recruitment by imatinib and TB03 was also accompanied by reduced secretion of epidermal (EGF) and basic fibroblast growth factors (bFGF; Figure 2c ). Media conditioned by K562 cells for 48 h treated with vehicle or TB03, imatinib or a combination of these two drugs, was collected and analyzed by immunoblotting a growth and angiogenesis factor array. Imatinib and TB03 each reduced bFGF secretion relative to the vehicle control by 450%, and by 66% when combined. EGF secretion was unaffected by either agent alone, but was reduced 40% by the combined treatment (Figure 2c ). Although leukemia cells do not express EGF receptors, 9 EGF promotes tumor angiogenesis in a variety of malignancies, 10 and several angiogenic regulators, including bFGF, appear to contribute to the survival of chronic lymphocytic leukemia (CLL) cells through as yet undefined mechanisms. 11 The emerging importance of microRNAs as gene regulators, their dysfunction in cancer and their potential utility as pharmacodynamic markers of imatinib/TB03 synergy prompted us to screen a microRNA array 12 to identify those significantly affected by treatment with TB03, imatinib or the two combined (Supplementary Table 2 ). Treatment with imatinib for 48 h modulated the expression of 13 microRNAs, 3 of which were also modulated by TB03. Of the 17 microRNAs modulated by imatinib plus TB03, 6 also responsive to either agent alone were modulated substantially more when the drugs were combined. Of the 17 microRNAs, 10 were unique to the combination, suggestive of distinct but complementary effects (Supplementary Table 2 ). The microRNAs affected most by these treatments have no known roles in cancer; hsa-miR-34b 13 and hsa-miR-30c 14 are tumor suppressors and miR-484 expression was found to be low in CLL patients developing autoimmune anemia (AHA), 15 so these results were validated by quantitative PCR. Drug effects on hsa-miR-30c were modest, consistent with microarray profiling, whereas the imatinib/TB03 combination significantly increased expression of hsa-miR-34b and hsa-miR-484 relative to either agent alone or vehicle controls (Po0.05, n ¼ 3; Supplementary Figure 3 ). If the upregulation of miR-484 by imatinib/TB03 in K562 cells can be extended to CLL cell models, further studies of its impact on AHA may be warranted. Hypermethylation of the miR-34b promoter in leukemia allows overexpression of the CREB proto-oncogene, thereby enhancing cell proliferation and altering normal differentiation. 13 Whether increased miR-34b expression associated with the combination of imatinib and TB03 in K562 was related to affects on promoter methylation is not yet clear, but such an effect in vivo would be anticipated to enhance treatment efficacy and also warrants further study.
In summary, synergistic inhibition of K562 leukemia cell proliferation by combined treatment with imatinib and a small molecule Grb2 SH2 domain binding antagonist was associated with cell cycle arrest, induction of apoptosis, reduced protein tyrosyl phosphorylation and Grb2 recruitment, suppression of a progenitor/stem cell subpopulation and increased expression of relevant tumor suppressor microRNAs. Further characterization of these effects could lead to improved diagnosis and more effective treatment of CML. Multiple myeloma (MM) has the highest incidence of bone involvement among malignant diseases. 1 Multiple myeloma bone disease (MMBD) is characterized by osteoclast (OCL) activation with suppressed or absent osteoblast (OBL) function resulting in local bone destruction without new bone formation. 2 IL-3 is a bifunctional cytokine that is upregulated in MM patients, increases myeloma cell and OCL proliferation and indirectly suppresses osteoblastogenesis via CD14 þ BM monocytes (BMM). 3, 4 However, the monocyte-/macrophage-derived mediators of IL-3's effects in MMBD are unknown.
To identify mediators of IL-3's bone remodeling effects in MM, we performed gene expression profiling of IL-3-treated MM patient CD14 þ peripheral blood cells, as previously described. 5 The INHBA gene, which codes for Activin A, 6 was upregulated 184-fold. The data in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE41992. ActA is a pluripotent TGF-b cytokine that stimulates osteoclastogenesis, inhibits OBLs and is overproduced in MM. In MM patients, ActA levels correlate with advanced disease and bone involvement, 7,8 thus we hypothesized that ActA mediates IL-3's bone effects in MM.
We confirmed our gene expression profiling findings by quantifying protein levels of IL-3-induced ActA production from healthy subjects as well as monoclonal gammopathy of undetermined significance (MGUS) and MM patient CD14 þ BMMs by enzymelinked immunosorbent assay (ELISA) (Quantikine human/mouse/rat Activin A ELISA kit, R&D Systems, Minneapolis, MN, USA). BM aspirates and peripheral blood samples were collected from healthy donors and MM or MGUS patients as previously described. 3 Studies were approved by each institution's Institutional Review Board. IL-3 induced a 70-fold increase in ActA production by MM patient-derived cells and a 10-fold increase in healthy donor samples.
As CD14 þ BMM are OCL precursors and IL-3 is a potent inducer of OCL formation, 3 we evaluated the role of ActA in IL-3-mediated OCL formation. Non-adherent BM cells from healthy subjects were cultured in the presence or absence of varying concentrations of cytokines or an ActA-neutralizing antibody (Anti-ActA) (R&D Systems) for 3 weeks, as previously described. 3 An isotypespecific mouse IgG was used as control for an anti-ActA antibody treatment. IL-3 treatment of OCL precursors in the presence of anti-ActA dose-dependently inhibited the osteoclastogenic effect of IL-3 on OCL formation (Figure 1a ). Consistent with these findings, ActA dose-dependently increased OCL formation with doses of 0.1 and 1 ng/ml (Figure 1b) .
We previously reported that the combination of RANKL and IL-3 enhances OCL formation over IL-3-induced osteoclastogenesis alone. 3 Thus, we next tested if IL-3 enhances osteoclastogenesis via a RANKL-independent mechanism. OCL precursors were treated with IL-3 and osteoprotegrin (OPG), the RANKL decoy receptor. OPG did not significantly reduce IL-3-induced OCL formation (Figure 1b) . Others have reported that ActA stimulates OCL differentiation in the presence of RANKL and MCSF. 8, 9 Accepted article preview online 26 December 2013; advance online publication, 17 January 2014
